Investors
Corporate Profile
2755 Bristol Street, Suite 285
Costa Mesa, CA 92626-5985 USA
phone: 714-545-3288
fax: 866-294-2611
Symbol: CNSO
Exchange: OB
Description
CNS Response is the first company to discover the basis for matching mental and addiction patient physiology to treatment outcomes (a biomarker system), thereby fundamentally altering the treatment of neuropsychiatric illness.
Products / Services
Referenced-EEG® (rEEG®) enhances a physician s ability to manage psychiatric medications in patients from 6 to 90 years of age. It has been proven useful in research and clinical use in patients with a broad range of diagnoses, including mood, anxiety, eating, obsessive-compulsive, traumatic, personality, and addictive disorders. rEEG® has proven particularly useful in what are called treatment-refractory patients - patients who have undergone numerous medication treatment trials with unsatisfactory results.
Technology / Differentiation
Medical treatment of mental disorders differs fundamentally from the treatment of all other health disturbances in that psychiatrists or addiction specialists have no objective physiologic brain measurement systems available to guide treatment of mental or addictive illness. rEEG uses digital electroencephalography in conjunction with a normative database and a proprietary clinical database to identify abnormal patient physiology.
Market / Customers
The psychiatric treatment market accounts for 7.4% of healthcare spending, second only to heart disease. In the U.S., depression affects more than 18 million people; physicians write 11 million prescriptions for depression per month. Other central nervous system disorders include anxiety, addiction, eating disorders and schizophrenia.
Status
CNS Response has developed the Referenced-EEG® (rEEG®) patented technology that utilizes common electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify abnormal patient physiology. The treatment has 80% effectiveness in retrospective and prospective studies, and in managed care, outpatient psychiatric and residential substance abuse clinical settings.